Lung cancer recurrence in the thyroid, initially mistaken for thyroid cancer

Patient Info: Anonymized, Male | Stage IV

Biomarkers: EGFR exon 19 deletion; TTF-1-positive; Napsin A-positive; PAX8-negative; thyroglobulin staining limited to tumour cells adjacent to normal thyroid tissue

Metastatic Site: thyroid; cervical lymph nodes

After starting osimertinib for EGFR exon 19-deleted recurrent lung adenocarcinoma, he was disease free 5 months after thyroid surgery.

PubMed CentralRead more →

HER2-positive metastatic lung cancer treated with trastuzumab deruxtecan (Enhertu)

Patient Info: Anonymized, Female | Stage IV

Biomarkers: ERBB2/HER2 copy-number gain of at least 20 copies; TP53 C242fs; CDK12 copy-number gain; tumour mutational burden 3.2 mutations/Mb

Metastatic Site: lungs / multiple pulmonary nodules

Trastuzumab deruxtecan reduced the pulmonary nodules by more than 50% at 3 months and produced a documented response lasting 13.8 months.

PubMed CentralRead more →

Rare lung sarcoma causing repeated collapsed lungs

Patient Info: Anonymized, Female | Stage I

Biomarkers: SS18-SSX2 fusion; CD99-positive; epithelial membrane antigen-positive; TLE1-positive; BCL-2-positive

She remained well under surveillance, with no evidence of disease on imaging at 3 years after definitive lobectomy.

PubMed CentralRead more →

Severe kidney inflammation after pembrolizumab for lung adenocarcinoma

Patient Info: Anonymized, Male, 60s

The primary lung tumor enlarged after pembrolizumab was stopped, and carboplatin plus paclitaxel was started in October 2021.

PubMed CentralRead more →

Afatinib-related kidney injury during treatment for EGFR-positive metastatic lung cancer

Patient Info: Anonymized, Male, 50s | Stage IV

Biomarkers: EGFR-positive.

Metastatic Site: pleura

He continued maintenance bevacizumab and atezolizumab after four combination courses for metastatic disease while his renal function remained impaired but stable.

PubMed CentralRead more →

Rare small cell lung cancer subtype removed by surgery

Patient Info: Anonymized, Male

Biomarkers: Cytokeratin-negative; focal TTF-1-positive; Napsin A-negative; electron microscopy showed neurosecretory granules; EWSR1 and SS18 rearrangement testing negative

Follow-up scans found no residual, recurrent or metastatic lung cancer, and he was doing well.

PubMed CentralRead more →

Stage IV EGFR Non-Small Cell Lung Cancer: Tiffany's Patient Story

Patient Info: Tiffany, Female | Stage IV

Biomarkers: EGFR mutation

Metastatic Site: Bone: pelvis, right femur, cervical spine

As of March 2023, Tiffany had benefited from Tagrisso plus Cyramza, but later CT findings suggested worsening disease and she had started a new early-stage clinical trial with results pending.

The Patient StoryRead more →

Small Cell Lung Cancer: Mary's Survivor Story

Patient Info: Mary Casanova, Female

As of March 2023, Mary described herself as healthy and in remission after chemotherapy and radiation for small cell lung cancer; stage and metastatic sites were not stated.

YouTube (ES search)Read more →

Lung cancer first discovered through a rare nerve disorder (anti-CV2 antibody syndrome)

Patient Info: Anonymized, Male

His lower-limb strength improved within 2 weeks, and he could walk 60 m with a rollator at discharge. On alectinib, the lung cancer remained stable with no metastases identified, and repeat nerve-conduction studies also improved.

PubMed CentralRead more →

Stage IV Lung Cancer Reached Remission After Severe Nerve Damage and Neck Surgery

Patient Info: Anonymized, Female | Stage IV

Metastatic Site: left cervical lymph nodes

Considered in complete remission after cervical lymph-node surgery, with no clinical or radiological progression 24 months after systemic treatment; alive and back at work 3 years after diagnosis.

PubMed CentralRead more →

Stage IV ALK Non-Small Cell Lung Cancer: Dan's Patient Story

Patient Info: Dan, Male, Under 40 | Stage IV

Biomarkers: ALK-positive / ALK-rearranged

As of November 2022, Dan was living with Stage IV ALK-positive non-small cell lung cancer on Alectinib, with stable scans since spring 2020 and ongoing monitoring.

The Patient StoryRead more →

Stage IV ALK Lung Cancer: Bekah's Patient Story

Patient Info: Bekah Cunningham, Female, Under 40 | Stage IV

Biomarkers: ALK-positive

Metastatic Site: breast

Maintenance scans remained clear 6 years after starting alectinib, and she continued to live an active life with Stage IV lung cancer.

Dana-FarberRead more →

Stage IV EGFR Lung Adenocarcinoma: Emily's Patient Story

Patient Info: Emily Bannister, Female, 40s | Stage IV

Biomarkers: EGFR Exon 19-positive; no other driver mutations present

Metastatic Site: Intrathoracic lymphatic spread

Emily had Stage IV EGFR Exon 19-positive lung adenocarcinoma with a strong early response to trial-based targeted therapy, and later passed away on March 14, 2023 from complications caused by Stage IV lung cancer.

Lung Cancer Research FoundationRead more →

Living with Stage 4 Lung Cancer (Plus Radiation & My Follow Up!) | Amy’s Story (3 of 3)

Patient Info: Amy, Female | Stage IV

Biomarkers: MET amplification

Metastatic Site: Bone/femur and hips; adrenal gland

As of July 2022, Amy was 3.5 years after Stage IV squamous cell lung cancer diagnosis, not NED but stable for about 3 years on Crizotinib with ongoing imaging and local treatment to lung/adrenal sites.

The Patient StoryRead more →

Pausing Alectinib During Pregnancy After a Complete Lung Cancer Response

Patient Info: Anonymized, Female | Stage IV

She remained in complete remission 32 months after diagnosis after pausing alectinib during pregnancy and restarting it after delivery; her child had normal physical and psychomotor development.

PubMed CentralRead more →

Stage IV MET Lung Squamous Cell Carcinoma: Amy's Patient Story

Patient Info: Amy, Female | Stage IV

Biomarkers: MET amplification

Metastatic Site: Bone/femur; lymph nodes; shoulder; adrenal glands;…

As of July 2022, Amy had a rapid and strong response to Crizotinib after MET amplification was found, with pain and lumps improving within about 2 weeks after Keytruda had failed.

The Patient StoryRead more →

Stage IV MET Non-Small Cell Lung Cancer: Amy's Patient Story

Patient Info: Amy, Female | Stage IV

Biomarkers: MET amplification identified later in the series; not known at initial treatment decision

As of July 2022, this first Amy segment covered diagnosis, second opinion, and the initial Keytruda-versus-clinical-trial decision before MET amplification was known; later response is addressed in the following series segments.

The Patient StoryRead more →

EGFR Non-Small Cell Lung Cancer: Karen's Patient Story

Patient Info: Karen Knetter, Female

Biomarkers: EGFR mutation

Karen lived 4 years after diagnosis with EGFR-mutated non-small cell lung adenocarcinoma and passed away on September 7, 2024.

Lung Cancer Research FoundationRead more →

Stage IV Lung Cancer: Shyreece's Patient Story

Patient Info: Shyreece Pompey, Female | Stage IV

Metastatic Site: Not reported

As of April 2022, Shyreece was living with Stage IV lung cancer and emphasized that speaking up in treatment decision-making helped her find the right doctor and treatment path.

The Patient StoryRead more →

Stage IV ALK Non-Small Cell Lung Cancer: Shyreece's Patient Story

Patient Info: Shyreece, Female | Stage IV

Biomarkers: ALK rearrangement / ALK-positive

Metastatic Site: Brain

As of March 2022, Shyreece was a long-term Stage IV ALK-positive lung cancer survivor with later brain metastases, ongoing treatment decisions, and advocacy focused on biomarker testing, trials, and disparities in Black lung cancer care.

The Patient StoryRead more →

Lung Cancer Patient Stories: Clinical Trials (& Patient Self-Advocacy!) | Shyreece’s Story (3 of 4)

Patient Info: Shyreece Pompey, Female | Stage IV

Biomarkers: Actionable biomarker identified by biomarker testing; specific mutation not stated

Metastatic Site: Not reported

As of March 2022, Shyreece was living with Stage IV lung cancer after moving from an initial chemotherapy cocktail to an unnamed targeted therapy pill and later participating in a clinical trial.

The Patient StoryRead more →

Stage IV ALK Lung Cancer: Shyreece's Patient Story

Patient Info: Shyreece Pompey, Female | Stage IV

Biomarkers: ALK-positive mutation identified by FISH testing

As of March 2022, Shyreece was living and advocating nearly 8 years after being diagnosed with Stage IV ALK-positive lung cancer; this segment does not report treatment response or a remission/NED status.

The Patient StoryRead more →

Lung adenocarcinoma found during evaluation of nephrotic syndrome and tuberculosis

Patient Info: Anonymized, Female, 50s

The right middle-lobe adenocarcinoma was resected, while nephrotic syndrome improved after surgery and treatment of the separate tuberculosis-related granuloma.

PubMed CentralRead more →

Severe kidney injury during pembrolizumab-based treatment for lung adenocarcinoma

Patient Info: Anonymized, Male, 70+

Kidney function stabilized during six months of follow-up, and he later began a modified cancer regimen containing SAR408701.

PubMed CentralRead more →